Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a pill replace chemo for stomach cancer in the elderly?

NCT ID NCT03219593

Disease control Sponsor: The First Affiliated Hospital of Bengbu Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 08, 2026 · Last updated Sep 09, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether apatinib, taken as a daily pill, can control advanced stomach or gastroesophageal junction cancer in people aged 65 and older who cannot or will not undergo chemotherapy. Participants receive apatinib until the disease worsens or side effects become intolerable. Researchers track how long the cancer stays stable and look for genetic markers that might predict who benefits.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
apatinib mesylate tablets
What this could lead to
If it works, apatinib could offer a gentler, chemotherapy-free option to control advanced gastric cancer in older adults who cannot tolerate chemo.
What could go wrong
This is a small, early-phase study with only 30 participants. Apatinib may not control the cancer, and side effects could force dose reductions or stop treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 30 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2017

Expected to finish

Sep 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with histologically proven primary locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma; 2. Age ≥ 65 years; 3. ECOG Performance Status: 0-2; 4. No previous anti-cancer therapy for the locally advanced or metastatic disease; 5. Unable or unwilling to chemotherapy; 6. At least one measurable lesion as defined by RECIST 1.1; 7. With acceptable hematologic, cardiac, hepatic, pulmonary and renal function; 8. Can take apatinib orally; 9. Life Expectancy: 3 months or more. Exclusion Criteria: 1. History of other primary malignancy (except basal cell skin cancer or cervical carcinoma in situ); 2. Patients with un-controlled blood pressure on medication (\> 140/90 mmHg); 3. Patients with other nonmeasurable disease such as un-controlled diabetes, severe cardiovascular and cerebrovascular diseases; 4. Patients with bleeding tendency, receiving thrombolytics or anticoagulants； 5. Patients with massive hydrothorax or ascites; 6. Patients with uncontrolled central nervous system (CNS) metastases; 7. Proteinuria 2+ or 24-hour urinary protein ≥ 1g; 8. History of drug addiction or abuse; 9. Patients cannot take apatinib orally for any reason; 10. Estimated life expectancy ˂ 3 months; 11. Current, recent (within 4 weeks prior to study entry), or planned participation in any other clinical trials; 12. Inability to understand and agree to informed consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Apatinib are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Apatinib Biomarker Gastric cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Medical Oncology, First Affiliated Hospital of Bengbu Medical College

    RECRUITING

    Bengbu, Anhui, 233004, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.